Akt pathway activation and increased neuropeptide Y mRNA expression in the rat hippocampus: implications for seizure

Eduardo M Goto1, Marcelo de Paula Silva, Sandra R Perosa

  • 1Pathology Department, Universidade Federal de São Paulo, UNIFESP, Brazil.

Neuropeptides
|January 13, 2010
PubMed

Insights

This study reveals that neuropeptide Y and Akt activation may play protective roles in epilepsy. Integrin-linked kinase (ILK) expression changes during the epileptic process, suggesting its involvement in neuroprotection.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Epilepsy Research

Background:

  • Epileptogenesis involves complex molecular changes in the brain.
  • Survival-related molecules and neuropeptides are implicated in seizure development and resolution.

Purpose of the Study:

  • To investigate the expression of Akt and integrin-linked kinase (ILK) during epileptogenesis.
  • To evaluate Akt pathway activation in the pilocarpine-induced epilepsy model.
  • To analyze the mRNA expression of neuropeptide Y, an antiepileptic neuropeptide.

Main Methods:

  • Pilocarpine-induced epilepsy model in male Wistar rats.
  • Real-Time PCR for mRNA expression analysis.
  • Immunohistochemistry for ILK distribution and Western blot for Akt activation.

Main Results:

  • ILK mRNA and protein levels decreased in acute and chronic epilepsy phases.
  • Akt activation increased during the silent phase of epilepsy.
  • Neuropeptide Y mRNA expression was elevated in the partial and silent phases.

Conclusions:

  • Neuropeptide Y may exert protective effects during epileptic phenomena.
  • Changes in ILK expression and Akt activation suggest their involvement in hippocampal neuroprotection during epilepsy.

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...